Akums Drugs & Pharmaceuticals Ltd

Akums Drugs & Pharmaceuticals Ltd

₹ 802 -0.69%
07 Nov - close price
About

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]

Key Points

Business Profile[1] Akums Drugs is a Contract Development and Manufacturing Organization (CDMO) manufacturing tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies.

  • Market Cap 12,629 Cr.
  • Current Price 802
  • High / Low 1,176 / 724
  • Stock P/E
  • Book Value
  • Dividend Yield 0.00 %
  • ROCE -13.1 %
  • ROE -50.7 %
  • Face Value 2.00

Pros

Cons

  • Company has low interest coverage ratio.
  • Company has a low return on equity of -33.5% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023 Mar 2024 Jun 2024
316 298 317
503 359 274
Operating Profit -187 -61 44
OPM % -59% -20% 14%
20 25 26
Interest 4 5 6
Depreciation 7 9 9
Profit before tax -178 -49 54
Tax % 6% 18% 23%
-190 -58 42
EPS in Rs -13.26 -4.05 2.84
Raw PDF
Upcoming result date: tomorrow

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
683 737 837 1,162 1,287 1,444
603 697 811 1,524 1,089 1,571
Operating Profit 80 40 27 -362 198 -127
OPM % 12% 5% 3% -31% 15% -9%
58 66 -195 58 -4 75
Interest 4 4 1 4 13 18
Depreciation 23 25 26 28 30 33
Profit before tax 112 76 -195 -335 150 -103
Tax % 33% 33% -26% 14% 17% 61%
75 51 -145 -382 125 -165
EPS in Rs 636.94 391.05 -1,118.18 -53.37 8.77 -11.56
Dividend Payout % 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 16%
3 Years: 20%
TTM: 12%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -170%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: -6%
3 Years: -34%
Last Year: -51%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 1 1 1 14 29
Reserves 841 711 566 171 283
51 36 41 140 188
153 678 690 1,488 1,395
Total Liabilities 1,046 1,426 1,298 1,814 1,894
220 242 244 253 272
CWIP 0 1 1 1 16
Investments 4 65 149 141 139
822 1,118 903 1,419 1,466
Total Assets 1,046 1,426 1,298 1,814 1,894

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-22 56 228 94
-242 -100 -298 -202
302 3 95 90
Net Cash Flow 38 -42 25 -18

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 85 88 92 95 73
Inventory Days 93 96 67 85 91
Days Payable 60 85 63 120 82
Cash Conversion Cycle 118 99 96 61 82
Working Capital Days 103 138 100 37 40
ROCE % 10% 8% -71% 74%

Shareholding Pattern

Numbers in percentages

Sep 2024
75.26%
7.34%
7.25%
7.42%
2.73%
No. of Shareholders 57,531

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents